Marian H. Hernandez Fernandez
YOU?
Author Swipe
View article: Supplementary Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Supplementary Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Figure S2. SMIP34 treatment downregulates liver specific genes, MYC and E2F pathway targeted genes in HCC cells.
View article: Supplementary Table 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Supplementary Table 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Supplementary Table 1. List of all the primers used for RT-qPCR.
View article: Supplementary Figure 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Supplementary Figure 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Figure S1. Levels of PELP1 expression in 6 HCC cell lines.
View article: Figure 5 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Figure 5 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
PELP1-KD or SMIP34 treatment suppresses HCC xenograft tumor growth in vivo. Hep3B–control and Hep3B–PELP1-KD model cells were injected subcutaneously into female (A, D, and G) or male SCID mice (
View article: Figure 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Figure 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
PELP1 expression is upregulated in HCC, and high PELP1 expression is associated with poor survival of patients with HCC. Data obtained from TNMplot shows increased expression of PELP1 in patients with HCC (A). The results from TCGA-…
View article: Supplementary Figure 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Supplementary Figure 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Figure S1. Levels of PELP1 expression in 6 HCC cell lines.
View article: Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
PELP1-KD/SMIP34 treatment decreased cell viability, clonogenicity, and invasiveness of HCC cells. PELP1-KD in Huh7 and Hep3B cell lines were confirmed by Western blot (A). Cell viability and clonogenic assays were performed t…
View article: Figure 3 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Figure 3 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Analysis of global transcriptional changes in PELP1-KD HCC cells. Volcano plot of differentially expressed genes with PELP1-KD in Hep3B cells is displayed (n = 3; A). PELP1-downregulated pathways were identified using …
View article: Data from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Data from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in the United States, with a median survival period of approximately 10 months. There is an urgent need for the development of effective targeted therapie…
View article: Figure 4 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Figure 4 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
SMIP34 treatment blocked PELP1-mediated extranuclear signaling and decreased global protein synthesis. Huh7, SNU398, Hep3B, and SNU423 cells were treated with vehicle (DMSO 0.01%) or SMIP34 (12.5 μmol/L) to examine PELP1 degradation and th…
View article: Supplementary Table 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Supplementary Table 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Supplementary Table 1. List of all the primers used for RT-qPCR.
View article: Supplementary Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
Supplementary Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Figure S2. SMIP34 treatment downregulates liver specific genes, MYC and E2F pathway targeted genes in HCC cells.
View article: PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma Open
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in the United States, with a median survival period of approximately 10 months. There is an urgent need for the development of effective targeted therapie…